Drugs / Measles-Mumps-Rubella vaccine (MMR)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05758532 | Mar 2023 → Apr 2026 overdue | allergic disease, dermatitis, respiratory tract infectious disorder | Laure Pittet, MD-PhD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles-Mumps-Rubella vaccine (MMR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05758532 ↗ |
| Known as | MMR | “Measles-Mumps-Rubella vaccine (MMR)” NCT05758532 ↗ |
| Modality | Vaccine | “MMR vaccine” NCT05758532 ↗ |
| Route | Intramuscular | “injected intramuscularly” NCT05758532 ↗ |